Date:10/1/2009

ing Life Science and High Technology company. Our chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

SOURCE Sigma-Aldrich

'/>"/>

SOURCE Sigma-Aldrich Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
3. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
4. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results